Foster City, CA, United States of America

Ernest A Carra

USPTO Granted Patents = 20 (Patent Applications = 3)

CIPO Patents = 5

EPO Patents = 7 (Patent Applications = 10)

Average Co-Inventor Count = 5.9

ph-index = 7

Forward Citations = 157(Granted Patents)

Company Filing History:

12 out of 919

Gilead Sciences, Inc.

Sierra Oncology, Inc.

Years Active: 2014-2025

Loading Chart...

20 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. RE50497 - (N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide (2025-07-22),

2. 12030906 - Crystalline forms of (s)-2-ethylbutyl 2-(((s)-(((2r,3s,4r,5r)-5-(4-aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methoxy) (phenoxy) phosphoryl)amino)propanoate (2024-07-09),

3. RE49445 - N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide (2023-03-06),

4. 11597742 - Crystalline forms of (S)-2-ethylbutyl 2-(((S)-(((2R,3S,4R,5R)-5-(4-aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methoxy) (phenoxy) phosphoryl)amino)propanoate (2023-03-07),

5. 11202780 - Crystalline forms of (2R,5S,13aR)-8-hydroxy-7,9-dioxo-N-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2′:4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide (2021-12-21),

6. 10946004 - Solid forms of an ASK1 inhibitor (2021-03-16),

7. 10836787 - Crystalline forms of (S)-2-ethylbutyl 2-(((S)-(((2R,3S,4R,5R)-5- (4-aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(phenoxy) phosphoryl)amino)propanoate (2020-11-17),

8. RE48285 - N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide (2020-10-26),

9. 10730879 - Polymorphic forms of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one (2020-08-04),

10. 10442805 - Polymorphic forms of a hydrochloride salt of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one (2019-10-15),

11. 10385067 - Sodium (2R,5S,13aR)-7,9-dioxo-10-((2,4,6-trifluorobenzyl)carbamoyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2′:4,5]pyrazino[2,1-b][1,3]oxazepin-8-olate (2019-08-20),

12. 10098886 - Crystalline forms of (2R,5S,13AR)-8-hydroxy-7,9-dioxo-N-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13A- octahydro-2,5-methanopyrido[1',2′:4,5]pyrazino[2,1-B] [1,3] oxazepine-10-carboxamide (2018-10-16),

13. 9809559 - (N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide (2017-11-07),

14. 9708342 - Sodium (2R,5S,13aR)-7,9-dioxo-10-((2,4,6-trifluorobenzyl)carbamoyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2′:4,5]pyrazino[2, 1-b][1, 3]oxazepin-8-olate (2017-07-18),

15. 9708327 - Polymorphic forms of a hydrochloride salt of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one (2017-07-18),

Title: The Innovations of Ernest A. Carra: A Pioneer in Pharmaceutical Patents

Introduction

Ernest A. Carra, based in Foster City, California, is an accomplished inventor with an impressive portfolio of 19 patents. His work primarily focuses on novel pharmaceutical compounds and their potential uses in treating viral infections. His significant contributions to the field of medicinal chemistry reflect his dedication and expertise in innovative drug development.

Latest Patents

Ernest A. Carra's latest patents include groundbreaking inventions such as crystalline forms of (S)-2-ethylbutyl 2-(((S)-(((2R,3S,4R,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate. This invention pertains to novel salts and crystalline forms that are used in treating viral infections caused by various viruses, including Arenaviridae, Coronaviridae, Filoviridae, Flaviviridae, and Paramyxoviridae. Another notable patent is for N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide, which outlines stable novel salt forms of this compound suitable for pharmaceutical formulations and highlights their therapeutic applications.

Career Highlights

Ernest A. Carra has built his career at esteemed companies such as Gilead Sciences, Inc. and Gilead Calistoga LLC. His work in these organizations has enabled him to develop innovative solutions for complex medical challenges, particularly in creating effective treatments for viral diseases.

Collaborations

Throughout his professional journey, Carra has collaborated with renowned colleagues, including Fang Wang and Bing Shi. These partnerships have fostered a rich environment for innovative research and contributed significantly to his success as an inventor.

Conclusion

Ernest A. Carra stands out as a key figure in the pharmaceutical innovation landscape. His 19 patents reflect a commitment to advancing medical technology and improving patient outcomes through novel drug formulations. As his work continues to evolve, the impact of Carra's contributions is likely to resonate in the healthcare industry for years to come.

This text is generated by artificial intelligence and may not be accurate.